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Abstract
Background: Hemodialysis patients are prone to constipation, which can adversely affect their quality of life (QOL).
Elobixibat, a highly selective inhibitor of the ileal bile acid transporter, can increase the bile acid level in the colon
and, subsequently, enhance colonic motility and secretion. In hemodialysis patients with chronic constipation, it
may have a novel action mechanism. However, the effect of elobixibat on such patients’ QOL had not been
reported. This study aimed to evaluate the effect of elobixibat on the QOL of hemodialysis patients with chronic
constipation.
Methods: This was a multicenter, observational study that used the Japanese version of the Patient Assessment of
Constipation-Quality of Life (PAC-QOL) questionnaire on 27 patients (18 men and nine women, age range 47–90
years), who satisfied the Rome 3 diagnostic criteria for functional constipation and were already taking other drugs
for constipation. These patients were administered elobixibat 10 mg/day and were asked to respond to the PAC-
QOL questionnaire at baseline and after 4 weeks. Bayesian statistics were used to confirm our results.
Results: The number of spontaneous bowel movements per week increased significantly from 2.6 ± 1.2 to 4.1 ± 2.1
(p < 0.001), and the Bristol Stool Form Scale score significantly improved from 1.9 ± 0.8 to 3.6 ± 0.7 (p < 0.001). The
Cronbach’s alpha was 0.95, and the Guttman split-half reliability coefficient was 0.90. There were significant
decreases in the physical discomfort scores from 1.94 ± 0.79 to 0.97 ± 0.72 (p < 0.001); psychosocial discomfort from
1.16 ± 0.93 to 0.63 ± 0.58 (p < 0.001); worries/ concerns from 1.84 ± 0.73 to 1.27 ± 0.59 (p < 0.001), and satisfaction
from 2.79 ± 0.61 to 1.98 ± 0.77 (p < 0.001). The total PAC-QOL score significantly decreased from 1.83 ± 0.79 to
1.17 ± 0.56 (p < 0.001). Bayesian statistics confirmed the results’ significance.
Conclusions: Elobixibat reduced the PAC-QOL scores for hemodialysis patients with chronic constipation and
improved the patients’ QOL. It may serve as a new option for treating constipation in hemodialysis patients.
Keywords: Hemodialysis patients, Constipation, Elobixibat, Bristol stool form scale, Patient assessment of
constipation-quality of life questionnaire
Background
Chronic constipation is a common condition that may
suggest digestive tract lesions, such as colon cancer, or
systemic diseases, such as thyroid disease. As the elderly
population increases, so does the number of patients
with chronic constipation. Chronic constipation greatly
impairs a patient’s quality of life (QOL), and improving
it can address both physical and mental QOL [1]. The
prevalence of chronic constipation in dialysis patients
based on evaluations using the Gastrointestinal Symp-
tom Rating Scale was reported to be 36.3–66.7% [2]. In
hemodialysis patients, constipation causes include water
restriction, water removal by dialysis, inadequate intake
of dietary fiber due to potassium restriction and the as-
sociated changes in intestinal microflora, lack of exer-
cise, decreased intestinal tract motility due to aging and
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muscle weakness, diabetic autonomic nervous system
disorder, intake of potassium inhibitors and phosphorus
adsorbents, and tolerance due to abuse of irritant
laxatives.
Elobixibat, a novel local-acting and highly selective
inhibitor of the ileal bile acid transporter that is
expressed in the terminal ileum, had been used to
treat chronic constipation and was shown to increase
bile acid levels in the colon, subsequently enhancing
colonic motility and secretion [3–6]. However, there
had been no reports on the efficacy of elobixibat in
hemodialysis patients with chronic constipation. This
aim of this study was to assess the efficacy of elobixi-
bat on the QOL and its effect on the Bristol Stool
Form Scale (BSFS) score and the number of spontan-
eous bowel movements (SBMs) per week of dialysis
patients with chronic constipation.
Methods
Subjects
We enrolled patients who answered the questionnaire
before and after elobixibat intake and who had taken
elobixibat in addition to other laxatives to relieve the
symptoms of chronic constipation. This retrospective
observational study was conducted by collecting data
from May 2018 to May 2019. We investigated 27 pa-
tients who were on maintenance dialysis three times per
week. Three patients underwent dialysis at the Tokyo
Women’s Medical University and 24 patients did at the
Nerima Sakuradai Clinic. All patients satisfied the Rome
3 diagnostic criteria for functional constipation and were
treated in accordance with the clinical guidelines of the
Japanese Society for Dialysis Therapy [7–11]. Written in-
formed consent was obtained from each study subject.
The study’s protocol was approved by Tokyo Women’s
Medical University’s ethics committee and was con-
ducted in accordance with the 2000 revised Helsinki
Declaration of 1975.
Data collection
Age, sex, weight, etiology of end-stage renal disease,
dialysis duration, comorbidities, laboratory data, the
Japanese version of the Patient Assessment of
Constipation-Quality of Life (PAC-QOL) questionnaire
[12, 13], self-reported BSFS score [14], and the number
of SBMs per week were obtained from the patients’
medical records. The conventional kinetic measure for
urea, known as the Kt/V (single pool), was used to esti-
mate the dialysis dose. The values of thyroid stimulat-
ing hormone, free triiodothyronine, free thyroxine, and
beta-2 microglobulin were based on the latest blood
collection.
Statistical analysis
Data were presented as mean ± standard deviation and
as medians and interquartile range. The PAC-QOL
score, BSFS score, and the number of SBMs per week
before and after 4 weeks of elobixibat intake were com-
pared using the Wilcoxon’s rank-sum test. Kendall rank
correlation coefficient was used to examine bivariate as-
sociations. According to the recommendations the of
American Statistical Association on P values [15, 16], we
used the SPSS Bayesian methods to confirm the stability
and robustness of our results. A value of p < 0.005 was
considered statistically significant. All statistical analyses
were performed with SPSS version 25.0 (IBM Corp.;
Armonk, NY, USA).
Results
Twenty-seven patients were enrolled in this study.
Tables 1 and 2 show the characteristics of enrolled pa-
tients. There were 18 men and nine women. The mean
age was 70 years, and the mean dialysis duration was 8
years. There were no patients with diseases that caused
colonic stenosis, such as colon cancer and Crohn’s
disease by abdominal echography, abdominal CT, or
colonoscopy. There were no patients with biliary atresia
and Parkinson’s disease. The types of the other laxatives
taken were one in 13 patients, two in 10 patients, and
three in 4 patients. There were no patients with liver
dysfunction. The patients did not show any liver dys-
function, psychoneurotic or circulatory illness, allergy,
blood cell abnormalities, or increased Creatine phospho-
kinase after taking Elobixibat.
Figure 1 shows the relationship between BSFS and
SBMs at the baseline. BSFS and SBMs were significantly
related (Kendall rank correlation coefficient tau = 0.650,
p < 0.001). Bayesian statistics confirmed the significance
of the result.
The internal consistency test result (Cronbach’s alpha)
of 0.956 and the reliability coefficient of 0.899, obtained
by Guttman’s split-half method, confirmed the PAC-
QOL questionnaire’s reliability. Table 3 shows the PAC-
QOL scores, SBMs, and BSFS score at baseline and after
4 weeks of elobixibat 10 mg/day intake. There were sig-
nificant decreases in the scores for physical discomfort
from 1.94 ± 0.79 to 0.97 ± 0.72 (p < 0.001); psychosocial
discomfort from 1.16 ± 0.93 to 0.63 ± 0.58 (p < 0.001);
worries/ concerns from 1.84 ± 0.73 to 1.27 ± 0.59 (p <
0.001); and satisfaction scores from 2.79 ± 0.61 to 1.98 ±
0.77 (p < 0.001). The total PAC-QOL score significantly
decreased from 1.83 ± 0.67 to 1.17 ± 0.56 (p < 0.001).
The number of SBMs per week increased significantly
from 2.6 ± 1.2 to 4.1 ± 2.1 (p < 0.001). BSFS scores at
baseline were “1” for 13 persons, “2” for 10 persons, “3”
for 2 persons, and “4” for 2 persons. BSFS scores at 4
Kamei et al. BMC Gastroenterology           (2020) 20:26 Page 2 of 8
weeks changed to “2” for 3 persons, “3” for 5 persons,
“4” for 18 persons, and “5” for 1 person. The BSFS score
significantly improved from 1.9 ± 0.8 to 3.6 ± 0.7 (p <
0.001). Bayesian statistics confirmed the results’
significance.
Figure 2 shows the relationship between changes in
BSFS and SBMs in 4-week elobixibat intake. BSFS and
SBMs were significantly related (Kendall rank correlation
coefficient tau = 0.468, p = 0.004). Bayesian statistics
moderately supported the significance of the result.
We divided the patients into two groups according to
the number of laxatives.
Tables 4 and 5 show the PAC-QOL scores, SBMs,
and BSFS scores at baseline and after 4 weeks in the
two groups.
As shown in Table 4, scores decreased for physical
discomfort from 1.79 ± 0.66 to 0.92 ± 0.53 (p = 0.004);
psychosocial discomfort from 0.94 ± 0.88 to 0.48 ± 0.47
(p = 0.017); worries/ concerns from 1.73 ± 0.74 to 1.24 ±
0.52 (p = 0.023); and satisfaction from 2.66 ± 0.54 to
2.09 ± 0.54 (p = 0.009). The total PAC-QOL score sig-
nificantly decreased from 1.68 ± 0.63 to 1.13 ± 0.42 (p =
0.002), whereas the number of SBMs per week increased
from 2.6 ± 1.2 to 4.1 ± 2.1 (p = 0.005). The BSFS score
significantly improved from 1.9 ± 0.0 to 3.6 ± 0.6 (p =
0.004). Bayesian statistics confirmed the significance of
these results.
As shown in Table 5, scores decreased for physical
discomfort from 2.07 ± 0.88 to 0.76 ± 0.64 (p = 0.002);
psychosocial discomfort from 1.36 ± 0.93 to 0.63 ± 0.58
Table 1 The characteristics of enrolled patients
Variable Mean ± SD and Median [IQR]
Number of enrolled patients 27
Sex (Male/Female) 18/9




Graft loss, 1 patient
Age (year) 70 ± 13, 75 [57, 80]
Dialysis duration (year) 8 ± 9, 6 [1,11]
Dry weight (kg) 58.1 ± 13.3, 58.1 [53.7, 61.5]
Single pool Kt/V 1.08 ± 0.25, 1.11 [0.86, 1.30]
Concomitant laxative 1 type drug: 13 patients
2 types drugs: 10 patients
3 types drugs: 4 patients
Type of concomitant laxative Sennosides A and B, 26 patients
Sodium picosulfate hydrate, 5 patients
Glycerine enema, 1 patient
Lactulose, 2 patients




Phosphate binder 0 drug, 3 patients
1 type of drug, 15 patients
2 types of drug, 9 patients
Type of phosphate binder Lantern carbonate, 6 patients
Calcium carbonate, 19 patients
Ferric citrate, 6 patients
Sucroferric oxyhydroxide, 2 patients
CGN chronic glomerulonephritis, ADPKD autosomal dominant polycystic kidney disease
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(p = 0.012); worries/ concerns from 1.95 ± 0.71 to 1.30 ±
0.65 (p = 0.002); and satisfaction from 2.90 ± 0.64 to
1.87 ± 0.93 (p = 0.004). The total PAC-QOL score sig-
nificantly decreased from 1.97 ± 0.68 to 1.21 ± 0.67 (p =
0.002), whereas the number of SBMs per week increased
from 2.3 ± 1.0 to 3.2 ± 1.5 (p = 0.027). The BSFS score
significantly improved from 1.8 ± 0.8 to 3.6 ± 0.8 (p =
0.002). Bayesian statistics confirmed the significance of
these results.
Table 6 shows the levels of electrolytes and choles-
terol at baseline and after 4 weeks of elobixibat 10
mg/day intake. Sodium, potassium, total calcium,
phosphate, LDL, and HDL did not change signifi-
cantly after elobixibat intake. Bayesian statistics con-
firmed the results.
Discussion
The present study revealed that supplemental adminis-
tration of elobixibat to hemodialysis patients with
chronic constipation improved their PAC-QOL, SBMs,
and BSFS, without significantly affecting the levels of so-
dium, potassium, total calcium, phosphate, LDL, and
HDL. Hard stools were significantly related to SBMs,
and softening stools were significantly related to increase
in SBMs.
Defecation is a necessary physiological function, and
its failure poses a major problem in daily life. The
prevalence of chronic constipation had been about
16% in the general population [17] and was reported
to be higher, at about 36 to 66%, in hemodialysis pa-
tients [2]. However, the reliability on self-reporting is
debatable when diagnosing constipation because pa-
tient’s perception may not accurately indicate the ac-
tual problem.
Constipation that does not improve and unpredict-
able defecation can cause gradual anxiety and dissatis-
faction, thereby restricting daily life activities. Indeed,
chronic constipation can greatly impair a patient’s
QOL, and addressing it was shown to improve both
physical and mental QOL [1]. We evaluated the QOL
of chronic constipation using PAC-QOL. PAC-QOL
is the most widely used disease-specific quality of life
measure for chronic constipation. In a recent study,
PAC-QOL was also used to evaluate various clinical
presentations of functional constipation, irritable
bowel syndrome with constipation, and No Rome
Constipation in Italy [18].
Treatment for chronic constipation usually begins
with diet and lifestyle improvement as well as appro-
priate exercise. If these changes do not help, medica-
tions or surgery may be recommended [19]. Chronic
constipation may also be associated with colonic or
rectal anatomo-functional alternations as colonic
inertia or rectal outlet obstruction, respectively. The
Table 2 The laboratory data of enrolled patients
Variable Mean ± SD, median [IQR]
Hemoglobin (g/dL) 10.7 ± 1.2, 10.7 [9.9, 11.7]
Total protein (g/dL) 6.3 ± 0.5, 6.4 [6.0, 6.6]
Albumin (g/dL) 3.4 ± 0.4, 3.4 [3.2, 3.6]
Blood urea nitrogen (mg/dL) 56.0 ± 13.2, 56.4 [45.1, 68.9]
Creatinine (mg/dL) 9.3 ± 3.0, 9.8 [6.9, 10.8]
Uremic acid (mg/dL) 7.1 ± 1.2, 7.3 [6.3, 7.9]
Aspartate aminotransferase (U/L) 14 ± 7, 12 [10, 14]
Alanine aminotransferase (U/L) 10 ± 6, 8 [7, 13]
Alkaline phosphatase (U/L) 251 ± 102, 217 [179, 291]
Lactate dehydrogenase (U/L) 200 ± 55, 191 [169, 208]
γ-glutamyltransferase (U/L) 24 ± 21, 17 [13, 25]
Total bilirubin (mg/dL) 0.3 ± 0.1, 0.2 [0.2, 0.3]
Cholinesterase (U/L) 195 ± 60, 182 [172, 219]
Creatine phosphokinase (U/L) 93 ± 75, 67 [45, 113]
Iron (μg/dL) 54 ± 25, 45 [35, 76]
Total iron binding capacity (μg/dL) 249 ± 46, 248 [215, 277]
Ferritin (ng/mL) 140 ± 148, 82 [32, 211]
Thyroid stimulating hormone (μU/mL) 2.13 ± 1.71, 1.55 [1.01, 2.59]
Free triiodothyronine (pg/mL) 1.97 ± 0.38, 2.04 [1.75, 2.29]
Free thyroxine (ng/dL) 1.00 ± 0.19, 1.01 [0.90, 1.09]
Intact parathyroid hormone (pg/mL) 155 ± 138, 110 [70, 203]
Beta 2 microglobulin (mg/L) 28.4 ± 9.1, 26.6 [23.1, 31.2]
Fig. 1 BSFS and SBMs in baseline. Kendall rank correlation
coefficient was 0.650 (P < 0.001). SBMs, spontaneous bowel
movements; BSFS, Bristol Stool Form Scale
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re-educative treatment and rehabilitation of the har-
mony of the “imaginary cuboid” constituted by the
diaphragm, abdominal wall, spine and pelvic floor
may be important [20–22].
Elobixbat is a pure enantiomer of synthetically
modified 1,5-benzothiazepine with a seven-membered
heterocyclic ring attached to a benzene ring (chemical
formula C36H45N3O7S2) [23, 24]. The main route of
elimination of elobixibat is in the feces. There is little
excretion in the urine. The estimated half-life in
humans is less than 4 h. The binding rate to human
plasma proteins in vitro is more than 99%, and the
human blood cell migration rate is less than 5%.
After oral ingestion of 14C-elobixibat, there was no
accumulation of elobixibat or associated metabolites
within the plasma or urine [23]. Multiple clinical
trials evaluating the use of elobixibat have demon-
strated consistent improvements in stool frequency
and consistency and clinically meaningful end points
across various populations diagnosed with chronic
idiopathic constipation [5, 6, 25–27]. However, no
studies have evaluated the use of this drug in dialysis
patients with chronic constipation. In the current
study, we demonstrated for the first time that adding
elobixibat to drugs for constipation improved
hemodialysis patients’ QOL.
Hemodialysis patients usually undergo dialysis three
times per week. If a patient feels the urge to defecate
during dialysis, the dialysis needs to be temporarily
stopped. If patients cannot make it to a toilet in time,
they may inadvertently excrete in the presence of
medical staff and other patients in the room, which
can cause great mental distress for patients. There-
fore, defecation on four non-dialysis days a week, and
avoiding defecation on dialysis days three times per
week may be desirable. In the current study, elobixi-
bat was shown to increase the number of SBMs from
2.6 to 4.1 times per week. Hemodialysis patients are
generally considered to pass hard stools because of
the restrictions in the intake of dietary fiber and
water, as well as water removal by dialysis. Aging-
associated muscle atrophy affects both skeletal and
Table 3 PAC-QOL, SBM, and Bayes factor at baseline and week 4
Baseline
Mean ± SD, median [IQR]
Week 4
Mean ± SD, median [IQR]
P value Bayes factor
PAC-QOL
Global score 1.83 ± 0.67 1.17 ± 0.56 < 0.001 < 0.001
1.93 [1.29, 2.36] 1.14 [0.71, 1.57]
Physical discomfort 1.94 ± 0.79 0.97 ± 0.72 < 0.001 < 0.001
2.00 [1.25, 2.50] 1.00 [0.50, 1.50]
Psychosocial discomfort 1.16 ± 0.93 0.63 ± 0.58 < 0.001 0.010
0.88 [0.25, 2.00] 0.50 [0.00, 1.00]
Worries and concerns 1.84 ± 0.73 1.27 ± 0.59 < 0.001 0.001
2.00 [1.09, 2.45] 1.18 [0.82, 1.91]
Satisfaction 2.79 ± 0.61 1.98 ± 0.77 < 0.001 0.002
2.80 [2.40, 3.40] 2.00 [1.60, 2.60]
Weekly SBM 2.6 ± 1.2 4.1 ± 2.1 < 0.001 < 0.001
2 [2, 3] 4 [2, 5]
Bristol Stool Form Scale score 1.9 ± 0.8 3.6 ± 0.7 < 0.001 0.007
2 [1, 2] 4 [3, 4]
PAC-QOL Patients Assessment of Constipation-Quality of Life, SBM spontaneous bowel movement
Fig. 2 Changes in BSFS and changes in SBMs after 4-week elobixibat
intake. Kendall rank correlation coefficient was 0.650 (P < 0.001).
SBMs, spontaneous bowel movements; BSFS, Bristol Stool
Form Scale
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smooth muscles, including those in the digestive tract,
thereby affecting digestive tract motor function [28].
In elderly dialysis patients, hard stools make
defecation more difficult. Elobixibat softens the stool
by inhibiting the reabsorption of bile acids. In this
study, elobixibat significantly improved the BSFS
score and changes in BSFS were related to changes in
SBMs. This implied that the softened stools made
defecation easier and increased weekly defecation
frequency, which may have led to the improvement in
the PAC-QOL.
Elobixibat was reported to lower serum LDL choles-
terol by approximately 10% [29]. However, in this study,
the LDL and HDL levels did not change significantly
after elobixibat administration for 4 weeks. Although
lubiprostone was reported to decrease serum IP levels in
hemodialysis patients [30], electrolytes did not change
significantly in this study.
Table 4 PAC-QOL, SBM, and Bayes factor at baseline and at week 4 in patients taking 1 laxative (N = 13)
Baseline
Mean ± SD, median [IQR]
Week 4
Mean ± SD, median [IQR]
P value Bayes factor
PAC-QOL
Global score 1.68 ± 0.63 1.13 ± 0.42 0.002 0.007
1.64 [1.14, 2.31] 1.00 [0.77, 1.34]
Physical discomfort 1.79 ± 0.66 0.92 ± 0.53 0.004 0.026
1.75 [1.00, 2.38] 0.75 [0.50, 1.13]
Psychosocial discomfort 0.94 ± 0.88 0.48 ± 0.47 0.017 0.285
0.75 [0.19, 1.57] 0.25 [0.07, 0.88]
Worries and concerns 1.73 ± 0.74 1.24 ± 0.52 0.023 0.219
2.00 [1.05, 2.32] 1.09 [0.82, 1.64]
Satisfaction 2.66 ± 0.54 2.09 ± 0.54 0.009 0.085
2.40 [2.30, 3.10] 1.80 [1.60, 2.50]
Weekly SBM 2.6 ± 1.2 4.1 ± 2.1 0.005 0.071
2 [2, 3] 4 [2, 5]
Bristol Stool Form Scale score 1.9 ± 0.9 3.6 ± 0.6 0.004 0.010
2 [1, 3] 4 [3, 4]
Table 5 PAC-QOL, SBM, and Bayes factor at baseline and week 4 in patients taking 2 or 3 laxatives (N = 14)
Baseline
Mean ± SD, median [IQR]
Week 4
Mean ± SD, median [IQR]
P value Bayes factor
PAC-QOL
Global score 1.97 ± 0.68 1.21 ± 0.67 0.002 0.009
2.00 [1.44, 2.52] 1.41 [0.43, 1.69]
Physical discomfort 2.07 ± 0.88 0.76 ± 0.64 0.002 0.020
2.00 [1.25, 2.75] 0.82 [0.00, 1.50]
Psychosocial discomfort 1.36 ± 0.93 0.63 ± 0.58 0.012 0.174
1.57 [0.56, 2.13] 0.50 [0.00, 1.00]
Worries and concerns 1.95 ± 0.71 1.30 ± 0.65 0.002 0.010
2.09 [1.29, 2.57] 1.45 [0.64, 1.96]
Satisfaction 2.90 ± 0.64 1.87 ± 0.93 0.004 0.056
3.00 [2.35, 3.45] 2.00 [1.10, 2.65]
Weekly SBM 2.3 ± 1.0 3.2 ± 1.5 0.027 0.363
2 [2, 3] 3 [2, 4]
Bristol Stool Form Scale score 1.8 ± 0.8 3.6 ± 0.8 0.002 0.001
2 [1, 2] 4 [3, 4]
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The present study had several limitations. First, this
study was conducted using questionnaires, and we could
not exclude the potential effects of other unknown con-
founders. Second, it was retrospective observational
study. Nevertheless, this was, to the best of our know-
ledge, the first multicenter observational study that eval-
uated the efficacy of elobixibat in hemodialysis patients
with chronic constipation. Furthermore, this study’s reli-
ability was confirmed by Bayesian inference. However,
further investigation on a larger sample size from mul-
tiple centers is necessary for external validity. Finally, the
generalizability of our results on the efficacy of elobixi-
bat in hemodialysis patients needs to be verified in a
large-scale, randomized controlled study with other
drugs or without elobixibat.
Conclusion
In conclusion, additional intake of elobixibat improved
the PAC-QOL score, BSFS score, and SBM frequency in
hemodialysis patients with chronic constipation, espe-
cially those with hard stools and poor stool rhythm. Fur-
ther investigation is necessary to ascertain our findings.
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